CD163 hi patients with pancreatic cancer had a shorter DFS (4.5 months vs 12.0 months, P = 0.0043) and OS (11.0 months vs 24.0 months, P = 0.0018) than 163 low patients (Figures 7A, B). This evidence concerns the gene CD163 and pancreatic neoplasm.